EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration

Nick Miles, Brian McNamee, Sharif I Soleman, Cindy Zadikoff, Joey Boiser, Loic Laplanche, Richard Burton, Mohamad Shebley, Ramesh R Boinpally

European Journal of Clinical Pharmacology · 2026-08 · 82 (8)

DOI: 10.1007/s00228-026-04078-8 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 21.07.2026. Verfasst von Nick Miles und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA. nick.miles@abbvie.com. Hauptthemen laut MEDLINE: Membrane Glycoproteins, Nerve Tissue Proteins. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane GlycoproteinsNerve Tissue ProteinsHumansMaleAdultMiddle AgedAdministration, OralHealthy VolunteersCarbon Radioisotopes

Stichwörter der Autor:innen

ABBV-552HumanMass balanceMetaboliteSynaptic vesicle glycoprotein 2A

Substanzen

SV2A protein, humanMembrane GlycoproteinsNerve Tissue ProteinsCarbon Radioisotopes

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA. nick.miles@abbvie.com.
  • Clinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.
  • Clinical Development Neuroscience, AbbVie Inc., North Chicago, IL, USA.
  • Global Patient Safety, AbbVie Inc., North Chicago, IL, USA.
  • Development Biological Sciences, AbbVie Inc., North Chicago, IL, USA.
  • Quantitative, Translational ADME Sciences, AbbVie Inc., North Chicago, IL, USA.

Förderung

  • AbbVie

Zitieren

APA

Miles, N., McNamee, B., Soleman, S. I., Zadikoff, C., Boiser, J., Laplanche, L., Burton, R., Shebley, M., & Boinpally, R. R. (2026). Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration. European Journal of Clinical Pharmacology, 82(8). https://doi.org/10.1007/s00228-026-04078-8

Vancouver

Miles N, McNamee B, Soleman SI, Zadikoff C, Boiser J, Laplanche L, et al. Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration. European Journal of Clinical Pharmacology. 2026;82(8). doi:10.1007/s00228-026-04078-8

BibTeX
@article{Miles2026,
  author = {Miles, Nick and McNamee, Brian and Soleman, Sharif I and Zadikoff, Cindy and Boiser, Joey and Laplanche, Loic and Burton, Richard and Shebley, Mohamad and Boinpally, Ramesh R},
  title = {Mass balance study of [14C]-ABBV-552, a synaptic vesicle glycoprotein 2A positive modulator, in healthy male participants following single oral dose administration},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {8},
  doi = {10.1007/s00228-026-04078-8}
}
Kostenlos starten →